Autoinflammatory & rare systemic diseases
Cancer incidence in Familial Mediterranean Fever: A retrospective analysis
Main finding · Cancer incidence vs the overall Turkish populationResult — go to the resultStandardized incidence ratio 0.64 95 % CI 0.46–0.89Authors' conclusion
Findings from our study indicate that the risk of cancer was decreased by 36 % in Turkish patients with FMF, compared with the outcomes of the overall Turkish population.
Study context
- Population
- Turkish patients with Familial Mediterranean Fever (FMF) registered at one division
- Participants
- 1,734 patients68,784 person-years
- Exposure
- Turkish FMF patients vs overall Turkish population
- FMFn = 1,734
- Outcome
- Cancer incidence (standardized incidence rates (SIR) vs Turkish population)
Methodological detailssingle-centre registry, standardised incidence ratio vs general population
- Single-centre registry
- Standardised incidence ratio vs general population
Main finding
As reported in the abstract
Cancer incidence vs the overall Turkish population
Standardized incidence ratio
0.64
95 % CI 0.46–0.89
P < 0.01
FMFvs Turkish population
SIR 0.64 (95 % CI 0.46–0.89); P < 0.01
Observational data: associations, not effects.
Further findings
Cancer and biological agent therapy (subgroup)
- No significant association between cancer and biological agent therapies in FMF patients
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Cancer incidence in Familial Mediterranean Fever: A retrospective analysis. Semin Arthritis Rheum. Published 2 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →